The current price of ACAD is $21.24 — it has decreased by 1.07% since the previous close. Data as of Nov 5, 2026.
ACAD is up 1.72% over the past week, up 5.62% over the past month and down 4.88% over the past year. The price is below its 200-day moving average of $23.60.
Analysts' average 12-month price target for ACAD is $29.95, which implies 41.01% upside from the current price. Individual estimates range from $14.50 to $37.00.
Acadia Pharmaceuticals Inc. has a market capitalization of $3.66B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Acadia Pharmaceuticals Inc. posted earnings of $0.31 per share against an estimate of $0.1992, beating expectations by 55.62%. Upcoming reports are listed in the earnings calendar.
Acadia Pharmaceuticals Inc. reported revenue of $342.29M in its most recent quarter, which has increased by 22.85% compared with the same quarter a year earlier. Analysts had expected $332.58M.
In the latest trading session ACAD moved between $21.14 and $22.63, a range of 7.02% of its current price.
Over the past 52 weeks ACAD has traded between $18.39 and $30.96. The current price is 31.40% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.